A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
Lartesertib achieved target exposure and engagement without significant hematological toxicity. Further clinical evaluation of lartesertib in combination therapy is ongoing.
Authors
- Lillian L. Siu (ORCID: https://orcid.org/0000-0002-3500-0540)
- Christine Hicking (ORCID: https://orcid.org/0009-0002-7750-8892)
- Deepthi S. Vagge (ORCID: https://orcid.org/0009-0000-9537-992X)
- Gregory Pennock (ORCID: https://orcid.org/0009-0008-5263-0625)
- Sofia Genta (ORCID: https://orcid.org/0000-0001-8441-2456)
- Anthony W. Tolcher (ORCID: https://orcid.org/0000-0002-6322-9721)
- Giuseppe Locatelli (ORCID: https://orcid.org/0009-0008-9163-7731)
- Jatinder Kaur Mukker (ORCID: https://orcid.org/0009-0007-7969-9238)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
Institutions
- University Health Network (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Princess Margaret Cancer Centre (CA)
- Ono Pharmaceutical (United States) (US)
- South Texas Accelerated Research Therapeutics (US)
- Kingston Health Sciences Centre (CA)
- Merck Serono S.p.A. (Italy) (IT)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1648
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- American Association for Cancer Research
- Amgen
- AstraZeneca
- GlaxoSmithKline
- Merck KGaA
- BeiGene